Hracs Lindsay, Windsor Joseph W, Gorospe Julia, Cummings Michael, Coward Stephanie, Buie Michael J, Quan Joshua, Goddard Quinn, Caplan Léa, Markovinović Ante, Williamson Tyler, Abbey Yvonne, Abdullah Murdani, Abreu Maria T, Ahuja Vineet, Raja Ali Raja Affendi, Altuwaijri Mansour, Balderramo Domingo, Banerjee Rupa, Benchimol Eric I, Bernstein Charles N, Brunet-Mas Eduard, Burisch Johan, Chong Vui Heng, Dotan Iris, Dutta Usha, El Ouali Sara, Forbes Angela, Forss Anders, Gearry Richard, Dao Viet Hang, Hartono Juanda Leo, Hilmi Ida, Hodges Phoebe, Jones Gareth-Rhys, Juliao-Baños Fabián, Kaibullayeva Jamilya, Kelly Paul, Kobayashi Taku, Kotze Paulo Gustavo, Lakatos Peter L, Lees Charlie W, Limsrivilai Julajak, Lo Bobby, Loftus Edward V, Ludvigsson Jonas F, Mak Joyce W Y, Miao YingLei, Ng Ka Kei, Okabayashi Shinji, Olén Ola, Panaccione Remo, Paudel Mukesh Sharma, Quaresma Abel Botelho, Rubin David T, Simadibrata Marcellus, Sun Yang, Suzuki Hidekazu, Toro Martin, Turner Dan, Iade Beatriz, Wei Shu Chen, Yamamoto-Furusho Jesus K, Yang Suk-Kyun, Ng Siew C, Kaplan Gilaad G
Division of Gastroenterology and Hepatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
Centre for Health Informatics and Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
Nature. 2025 Apr 30. doi: 10.1038/s41586-025-08940-0.
During the twentieth century, inflammatory bowel disease (IBD) was considered a disease of early industrialized regions in North America, Europe and Oceania. At the turn of the twenty-first century, IBD incidence increased in newly industrialized and emerging regions in Africa, Asia and Latin America, while the prevalence in early industrialized regions continued to grow steadily. Changes in the incidence and prevalence denote the evolution of IBD across four epidemiologic stages: stage 1 (emergence), characterized by low incidence and prevalence; stage 2 (acceleration in incidence), marked by rapidly rising incidence and low prevalence; and stage 3 (compounding prevalence), where the incidence decelerates, plateaus or declines while the prevalence steadily increases. A fourth stage (prevalence equilibrium) has been proposed in which the prevalence slope plateaus due to demographic shifts in an ageing IBD population, but it has not yet been evidenced. To date, these stages have remained theoretical, lacking specific numerical indicators to define transition points. Here, using real-world data from 522 population-based studies encompassing 82 global regions and spanning more than a century (1920-2024), we show spatiotemporal transitions across stages 1-3 and model stage 4 progression. Understanding the evolution of IBD across epidemiologic stages enables healthcare systems to better anticipate the future worldwide burden of IBD.
在二十世纪,炎症性肠病(IBD)被认为是北美、欧洲和大洋洲早期工业化地区的一种疾病。在二十一世纪之交,IBD在非洲、亚洲和拉丁美洲的新兴工业化地区发病率上升,而早期工业化地区的患病率继续稳步增长。发病率和患病率的变化表明IBD在四个流行病学阶段的演变:第一阶段(出现),其特征是发病率和患病率较低;第二阶段(发病率加速),其特征是发病率迅速上升且患病率较低;第三阶段(患病率增加),在此阶段发病率下降、趋于平稳或下降,而患病率稳步上升。有人提出了第四阶段(患病率平衡),即在IBD患者老龄化导致人口结构变化的情况下,患病率斜率趋于平稳,但尚未得到证实。迄今为止,这些阶段仍停留在理论层面,缺乏定义转变点的具体数值指标。在此,我们利用来自522项基于人群的研究的真实世界数据,这些研究涵盖82个全球地区,跨越一个多世纪(1920 - 2024年),展示了IBD在第1 - 3阶段的时空转变,并对第4阶段的进展进行建模。了解IBD在各个流行病学阶段的演变,有助于医疗系统更好地预测全球未来IBD的负担。